Novel compound appears to protect mice against movement problems associated with PD

Scientists report that they have developed a novel compound that appears to protect mice against developing movement problems associated with Parkinson's disease (PD). The research, which could one day in the future translate into a therapy that could halt the progression of PD and thereby prevent the symptoms of the disease, appears in ACS' Journal of Medicinal Chemistry.

Onyou Hwang, Ki Duk Park and colleagues explain that PD, which affects an estimated 4 million to 10 million people worldwide, is a progressive movement disorder with no known cure. It often starts with slight tremors and gets worse over time. Muscles go stiff. Walking becomes difficult. Speech is slurred. No one knows for certain what causes the disease, but research has shown that it's linked with the loss of nerve cells in the brain that secrete dopamine, a chemical that is involved in movement and emotion. To find a potential new therapy for PD, the research team searched for a way to shield these brain cells.

They made 56 compounds and tested them to see which ones boosted the production of proteins that protect dopamine-releasing neurons from damage. Of those, one, which they call "12g," proved to be the most active. Interestingly, it protected mice from developing PD-like symptoms in one laboratory test. "Taken together, 12g was found to effectively prevent the motor deficits that are associated with PD," they say.

Source: American Chemical Society

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study highlights the potential of psilocybin in treating obsessive-compulsive disorder